Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (6): 563-568.DOI: 10.3969/j.issn.1673-8640.2023.06.011
Previous Articles Next Articles
JIN Suli, ZHAO Jing, ZHANG Jie, HOU Xuening, FANG Yanchao, YANG Li, MI Yujing()
Received:
2022-08-17
Revised:
2023-04-14
Online:
2023-06-30
Published:
2023-08-22
CLC Number:
JIN Suli, ZHAO Jing, ZHANG Jie, HOU Xuening, FANG Yanchao, YANG Li, MI Yujing. Relationship between thyroid hormones and bile acid subfractions and blood lipids in Graves' disease patients[J]. Laboratory Medicine, 2023, 38(6): 563-568.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.06.011
组别 | 例数 | hs-TSH/(mIU/L) | FT3/(pmol/L) | FT4/(pmol/L) | FBG/(mmol/L) | TG/(mmol/L) |
---|---|---|---|---|---|---|
GD组 | 43 | 0.01(0.01,0.04) | 8.02(6.14,11.20) | 22.01(12.05,31.76) | 5.18(4.77,5.64) | 1.14±0.23 |
正常对照组 | 36 | 2.39(1.90,2.82) | 4.63(4.04,4.86) | 10.85(9.57,11.95) | 5.17(4.36,5.70) | 1.23±0.49 |
统计值 | -7.777 | -6.817 | -5.262 | -0.930 | -0.93 | |
P值 | <0.001 | <0.001 | <0.001 | 0.352 | 0.375 | |
组别 | TC/(mmol/L) | HDL-C/(mmol/L) | LD-CL/(mmol/L) | ALT/(U/L) | AST/(U/L) | |
GD组 | 3.63(3.32,4.64) | 1.13(1.00,1.21) | 2.61±0.69 | 17.90(12.80,22.70) | 18.90(16.80,23.80) | |
正常对照组 | 4.71(3.75,5.29) | 1.26(1.18,1.50) | 2.97±0.79 | 14.30(11.52,22.55) | 17.90(13.85,25.95) | |
统计值 | -3.028 | -4.323 | -2.134 | -1.531 | -1.502 | |
P值 | 0.002 | 0.001 | 0.036 | 0.126 | 0.133 |
组别 | 例数 | hs-TSH/(mIU/L) | FT3/(pmol/L) | FT4/(pmol/L) | FBG/(mmol/L) | TG/(mmol/L) |
---|---|---|---|---|---|---|
GD组 | 43 | 0.01(0.01,0.04) | 8.02(6.14,11.20) | 22.01(12.05,31.76) | 5.18(4.77,5.64) | 1.14±0.23 |
正常对照组 | 36 | 2.39(1.90,2.82) | 4.63(4.04,4.86) | 10.85(9.57,11.95) | 5.17(4.36,5.70) | 1.23±0.49 |
统计值 | -7.777 | -6.817 | -5.262 | -0.930 | -0.93 | |
P值 | <0.001 | <0.001 | <0.001 | 0.352 | 0.375 | |
组别 | TC/(mmol/L) | HDL-C/(mmol/L) | LD-CL/(mmol/L) | ALT/(U/L) | AST/(U/L) | |
GD组 | 3.63(3.32,4.64) | 1.13(1.00,1.21) | 2.61±0.69 | 17.90(12.80,22.70) | 18.90(16.80,23.80) | |
正常对照组 | 4.71(3.75,5.29) | 1.26(1.18,1.50) | 2.97±0.79 | 14.30(11.52,22.55) | 17.90(13.85,25.95) | |
统计值 | -3.028 | -4.323 | -2.134 | -1.531 | -1.502 | |
P值 | 0.002 | 0.001 | 0.036 | 0.126 | 0.133 |
组别 | 例数 | CA/(nmol/L) | CDCA/(nmol/L) | GCA/(nmol/L) |
---|---|---|---|---|
GD组 | 43 | 90.79(40.63,288.19) | 305.77(169.40,897.60) | 183.83(76.04,457.99) |
正常对照组 | 36 | 59.84(30.65,163.64) | 200.70 (56.07,640.72) | 144.39(77.30,524.26) |
Z值 | -1.349 | -1.816 | -0.404 | |
P值 | 0.177 | 0.069 | 0.687 | |
组别 | GCDCA/(nmol/L) | TCA/(nmol/L) | TCDCA/(nmol/L) | DCA/(nmol/L) |
GD组 | 2 101.43(919.03,4 723.80) | 44.63(18.58,93.14) | 248.27(122.71,464.98) | 143.50(83.99,244.73) |
正常对照组 | 1 843.58(783.65,4 323.40) | 28.83(17.65,101.74) | 182.93(109.80,406.47) | 350.94(108.74,618.95) |
Z值 | -0.315 | -0.433 | -0.325 | -2.803 |
P值 | 0.753 | 0.665 | 0.745 | 0.005 |
组别 | LCA/(nmol/L) | UDCA/(nmol/L) | GDCA/(nmol/L) | GLCA/(nmol/L) |
GD组 | 7.87(4.38,14.63) | 109.86(50.98,169.91) | 170.40(95.55,311.42) | 8.00(5.00,14.24) |
正常对照组 | 5.80(2.07,12.21) | 137.41(81.49,365.34) | 368.85(109.29,765.53) | 6.36(5.00,14.13) |
Z值 | -1.304 | -2.269 | -2.235 | -1.279 |
P值 | 0.192 | 0.023 | 0.025 | 0.201 |
组别 | LCA/(nmol/L) | UDCA/(nmol/L) | GDCA/(nmol/L) | GLCA/(nmol/L) |
GD组 | 7.87(4.38,14.63) | 109.86(50.98,169.91) | 170.40(95.55,311.42) | 8.00(5.00,14.24) |
正常对照组 | 5.80(2.07,12.21) | 137.41(81.49,365.34) | 368.85(109.29,765.53) | 6.36(5.00,14.13) |
Z值 | -1.304 | -2.269 | -2.235 | -1.279 |
P值 | 0.192 | 0.023 | 0.025 | 0.201 |
组别 | GUDCA/(nmol/L) | TDCA/(nmol/L) | TLCA/(nmol/L) | TUDCA/(nmol/L) |
GD组 | 275.37(138.47,533.33) | 37.33(13.78,84.34) | 5.00(5.00,6.78) | 10.00(10.00,14.69) |
正常对照组 | 477.69(209.59,996.91) | 41.80(20.28,83.91) | 5.00(5.00,6.72) | 14.49(10.00,27.28) |
Z值 | -2.215 | -0.591 | -0.304 | -2.121 |
P值 | 0.027 | 0.554 | 0.761 | 0.034 |
组别 | 例数 | CA/(nmol/L) | CDCA/(nmol/L) | GCA/(nmol/L) |
---|---|---|---|---|
GD组 | 43 | 90.79(40.63,288.19) | 305.77(169.40,897.60) | 183.83(76.04,457.99) |
正常对照组 | 36 | 59.84(30.65,163.64) | 200.70 (56.07,640.72) | 144.39(77.30,524.26) |
Z值 | -1.349 | -1.816 | -0.404 | |
P值 | 0.177 | 0.069 | 0.687 | |
组别 | GCDCA/(nmol/L) | TCA/(nmol/L) | TCDCA/(nmol/L) | DCA/(nmol/L) |
GD组 | 2 101.43(919.03,4 723.80) | 44.63(18.58,93.14) | 248.27(122.71,464.98) | 143.50(83.99,244.73) |
正常对照组 | 1 843.58(783.65,4 323.40) | 28.83(17.65,101.74) | 182.93(109.80,406.47) | 350.94(108.74,618.95) |
Z值 | -0.315 | -0.433 | -0.325 | -2.803 |
P值 | 0.753 | 0.665 | 0.745 | 0.005 |
组别 | LCA/(nmol/L) | UDCA/(nmol/L) | GDCA/(nmol/L) | GLCA/(nmol/L) |
GD组 | 7.87(4.38,14.63) | 109.86(50.98,169.91) | 170.40(95.55,311.42) | 8.00(5.00,14.24) |
正常对照组 | 5.80(2.07,12.21) | 137.41(81.49,365.34) | 368.85(109.29,765.53) | 6.36(5.00,14.13) |
Z值 | -1.304 | -2.269 | -2.235 | -1.279 |
P值 | 0.192 | 0.023 | 0.025 | 0.201 |
组别 | LCA/(nmol/L) | UDCA/(nmol/L) | GDCA/(nmol/L) | GLCA/(nmol/L) |
GD组 | 7.87(4.38,14.63) | 109.86(50.98,169.91) | 170.40(95.55,311.42) | 8.00(5.00,14.24) |
正常对照组 | 5.80(2.07,12.21) | 137.41(81.49,365.34) | 368.85(109.29,765.53) | 6.36(5.00,14.13) |
Z值 | -1.304 | -2.269 | -2.235 | -1.279 |
P值 | 0.192 | 0.023 | 0.025 | 0.201 |
组别 | GUDCA/(nmol/L) | TDCA/(nmol/L) | TLCA/(nmol/L) | TUDCA/(nmol/L) |
GD组 | 275.37(138.47,533.33) | 37.33(13.78,84.34) | 5.00(5.00,6.78) | 10.00(10.00,14.69) |
正常对照组 | 477.69(209.59,996.91) | 41.80(20.28,83.91) | 5.00(5.00,6.72) | 14.49(10.00,27.28) |
Z值 | -2.215 | -0.591 | -0.304 | -2.121 |
P值 | 0.027 | 0.554 | 0.761 | 0.034 |
[1] | 刘璇. 2型糖尿病合并甲状腺疾病的患病情况和影响因素分析[D]. 兰州: 兰州大学, 2018. |
[2] | SHIN D J, WANG L. Bile acid-activated receptors:a review on FXR and other nuclear receptors[J]. Handb Exp Pharmacol, 2019, 256:51-72. |
[3] |
FIORUCCI S, DISTRUTTI E, CARINO A, et al. Bile acids and their receptors in metabolic disorders[J]. Prog Lipid Res, 2021, 82:101094.
DOI URL |
[4] |
XU Y. Recent progress on bile acid receptor modulators for treatment of metabolic diseases[J]. J Med Chem, 2016, 59(14):6553-6579.
DOI PMID |
[5] | 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 甲状腺功能亢进症基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2019, 18(12):1118-1128. |
[6] | 倪青. 甲状腺功能亢进症病证结合诊疗指南(2021-01-20)[J]. 世界中医药, 2021, 16(2):193-196. |
[7] | 张春玉, 曾洪利, 刘颖, 等. 甲状腺结节与代谢综合征及其组分的相关性分析[J]. 中华内分泌代谢杂志, 2012, 28(2):132-135. |
[8] |
SONG Y, ZHAO M, ZHANG H, et al. Thyroid-stimulating hormone levels are inversely associated with serum total bile acid levels:a cross-sectional study[J]. Endocr Pract, 2016, 22(4):420-426.
DOI URL |
[9] | 符静, 刘佳, 王广. 胆汁酸代谢产物与Graves病患者甲状腺功能的相关性探讨[J]. 解放军医学院学报, 2021, 42(8):802-807. |
[10] | 毕叶. 甲状腺功能异常对人血清胆汁酸谱的影响[D]. 济南: 山东大学, 2012. |
[11] |
CHIANG J Y L, FERRELL J M. Discovery of farnesoid X receptor and its role in bile acid metabolism[J]. Mol Cell Endocrinol, 2022, 548:111618.
DOI URL |
[12] |
JIA W, XIE G, JIA W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(2):111-128.
DOI PMID |
[13] |
JIANG L, ZHANG H, XIAO D, et al. Farnesoid X receptor(FXR):structures and ligands[J]. Comput Struct Biotechnol J, 2021, 19:2148-2159.
DOI URL |
[14] |
CHIANG J Y L, FERRELL J M. Up to date on cholesterol 7 alpha-hydroxylase(CYP7A1) in bile acid synthesis[J]. Liver Res, 2020, 4(2):47-63.
DOI URL |
[15] |
LANGE T, BUDDE K, HOMUTH G, et al. Comprehensive metabolic profiling reveals a lipid-rich fingerprint of free thyroxine far beyond classic parameters[J]. J Clin Endocrinol Metab, 2018, 103(5):2050-2060.
DOI PMID |
[16] | YANG F, XU W, WU L, et al. NTCP deficiency affects the levels of circulating bile acids and induces osteoporosis[J]. Front Endocrinol(Lausanne), 2022, 13:898750. |
[17] |
DONKERS J M, ROSCAM ABBING R L P, VAN WEEGHEL M, et al. Inhibition of hepatic bile acid uptake by myrcludex B promotes glucagon-like peptide-1 release and reduces obesity[J]. Cell Mol Gastroenterol Hepatol, 2020, 10(3):451-466.
DOI PMID |
[18] | 徐润灏, 邹琛, 张洁, 等. 胆汁酸谱在肺炎和肺癌鉴别诊断中的应用价值[J]. 检验医学, 2021, 36(1):1-7. |
[19] | 赵元辰, 崔乃强. 胆汁酸与肠道菌群相关性研究进展[J]. 中国中西医结合外科杂志, 2018, 24(5):666-671. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||